Biodexa Pharmaceuticals (BDRX) Other Non-Current Liabilities (2016 - 2022)
Biodexa Pharmaceuticals (BDRX) posted Other Non-Current Liabilities of $242796.2 for Q4 2022, up 348.37% sequentially from $54150.5 in Q2 2022, and up 260.23% YoY from $67400.5 in Q4 2021.
Biodexa Pharmaceuticals (BDRX) Other Non-Current Liabilities (2016 - 2022) Analysis & Trends
Biodexa Pharmaceuticals has reported Other Non-Current Liabilities for 6 years, with the latest figure at $242796.2 in Q4 2022.
- Quarterly Other Non-Current Liabilities rose 260.23% year-over-year to $242796.2 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $242796.2 (up 260.23% YoY) and the FY2022 annual result came in at $256185.1, up 272.39% from the prior year.
- Other Non-Current Liabilities improved to $242796.2 in Q4 2022 per BDRX's latest filing, from $54150.5 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $242796.2 in Q4 2022 and troughed at $54150.5 in Q2 2022.
- A 5-year average of $131191.2 and a median of $97300.9 in 2019 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2020 and 2022: Other Non-Current Liabilities sank 47.06% in 2020, then jumped 260.23% in 2022.
- Over 5 years, Other Non-Current Liabilities stood at $212316.6 in 2018, then slumped by 41.26% to $124715.3 in 2019, then tumbled by 47.06% to $66022.6 in 2020, then grew by 2.09% to $67400.5 in 2021, then surged by 260.23% to $242796.2 in 2022.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $242796.2, $54150.5, and $67400.5 for Q4 2022, Q2 2022, and Q4 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 242,796.16 |
| Jun 30, 2022 | 54,150.51 |
| Dec 31, 2021 | 67,400.53 |
| Jun 30, 2021 | 69,886.41 |
| Dec 31, 2020 | 66,022.55 |
| Dec 31, 2019 | 124,715.32 |
| Jun 30, 2019 | 212,241.58 |
| Dec 31, 2018 | 212,316.59 |
| Jun 30, 2016 | 1.15 Mn |